An Innovative, FDA-Authorized Treatment to Help Improve Vision

Mississippi Retina Associates is proud to offer the Valeda Light Delivery System, the first FDA-authorized photobiomodulation (PBM) therapy for certain patients with dry age-related macular degeneration (AMD).

This noninvasive treatment uses specialized wavelengths of light to help improve vision, offering a new option for eligible patients living with one of the leading causes of vision loss in older adults.

Understanding Dry Age-Related Macular Degeneration

Dry age-related macular degeneration is a progressive eye disease that affects the macula, the part of the retina responsible for sharp, central vision. As the disease develops, patients may experience blurred central vision, difficulty reading, or trouble recognizing faces. Although dry AMD generally progresses gradually, changes to central vision can significantly affect everyday activities.

Until recently, treatment options for improving vision in patients with dry AMD were limited.

How Does Valeda Light Therapy Work?

Valeda uses a technology called photobiomodulation, which delivers specific wavelengths of red, yellow, and near-infrared light to the retina.

This light-based therapy is designed to support cellular function within the retina. Clinical studies have demonstrated improvements in visual acuity among certain patients with dry AMD.

Unlike treatments that require injections or surgery, Valeda is noninvasive and does not involve medications.

What Can Patients Expect During Treatment?

Valeda treatments are performed in a clinical setting and take just a few minutes per eye. Patients sit comfortably in front of the device while carefully controlled light is directed toward the eyes. No needles, injections, or incisions are required.

A typical treatment series includes nine sessions over three to five weeks. Additional treatment series may be recommended based on the patient’s individual care plan.

Who May Benefit from Valeda?

Valeda is intended for certain patients with dry AMD who meet specific clinical criteria. The FDA authorization includes patients with particular retinal changes and best-corrected vision between 20/32 and 20/70. Patients with certain advanced forms of macular degeneration may not qualify.

While clinical studies have demonstrated improvements in visual acuity, individual results vary. Valeda is not a cure for macular degeneration, and it does not restore all vision that may have been lost.

A comprehensive retinal evaluation is necessary to determine whether this treatment may be appropriate.

Advanced Macular Degeneration Care at Mississippi Retina Associates

At Mississippi Retina Associates, we are committed to providing patients with access to advancements in retinal disease treatment.

The addition of the Valeda Light Delivery System expands our treatment options for eligible patients with dry age-related macular degeneration.

If you have been diagnosed with dry AMD or have noticed changes in your central vision, contact Mississippi Retina Associates at 601-981-4091 to learn more about Valeda and schedule a retinal evaluation.

Treatment eligibility, expected benefits, potential risks, and recommended treatment schedules should be discussed with your retinal specialist.